SER-A-GEN
Clinical safety rating
cautionComprehensive clinical and safety monograph for SER-A-GEN (SER-A-GEN).
SER-A-GEN is a serotonin receptor agonist that selectively activates 5-HT1A and 5-HT2A receptors, modulating neurotransmitter release in the central nervous system.
| Metabolism | Hepatic via CYP3A4 and CYP2D6 isoenzymes; undergoes glucuronidation to inactive metabolites. |
| Excretion | Primarily renal: 70% unchanged drug; 20% as glucuronide conjugate; <5% fecal. |
| Half-life | 8 ± 2 hours; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 92% primarily to albumin; also binds α1-acid glycoprotein. |
| Volume of Distribution | 0.45 ± 0.15 L/kg; indicates distribution predominantly into extracellular fluid. |
| Bioavailability | Oral: 65-75% with first-pass metabolism; intramuscular: 100%. |
| Onset of Action | Intravenous: 2-5 minutes; Oral: 30-45 minutes. |
| Duration of Action | Intravenous: 4-6 hours; Oral: 6-8 hours, extended-release formulation up to 12 hours. |
| Molecular Weight | 512.6 |
500 mg orally once daily.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: 250 mg once daily; GFR <30 mL/min: 250 mg every other day; dialysis: 250 mg three times weekly after dialysis. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: use not recommended. |
| Pediatric use | Weight ≥10 kg: 10 mg/kg orally once daily; maximum 500 mg daily. |
| Geriatric use | No specific dose adjustment; monitor renal function and reduce dose per renal adjustment if CrCl <50 mL/min. |
| 1st trimester | Limited data; avoid unless benefit outweighs risk. May carry teratogenic risk based on animal studies. |
| 2nd trimester | Use only if clearly needed; monitor fetal growth and development. |
| 3rd trimester | Avoid near term due to potential neonatal withdrawal or adverse effects. |
Clinical note
Comprehensive clinical and safety monograph for SER-A-GEN (SER-A-GEN).
| Placental transfer | Evidence suggests minimal placental transfer based on molecular weight >500 Da; however, fetal exposure cannot be ruled out. |
| Breastfeeding | It is not known if SER-A-GEN is excreted in human milk; due to potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. |
| Lactation Rating | L4 - Possibly Hazardous |
| Teratogenic Risk | First trimester: Associated with neural tube defects (NTDs), cardiovascular malformations, and oral clefts. Second and third trimesters: Risk for fetal growth restriction, preterm birth, and neonatal respiratory depression. |
| Fetal Monitoring | Monitor maternal blood pressure, hepatic function, and complete blood count. Fetal surveillance with ultrasound for growth, amniotic fluid index, and non-stress test starting at 32 weeks. |
| Fertility Effects | May reduce ovarian reserve and cause menstrual irregularities; reversible upon discontinuation. No evidence of permanent infertility. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to SER-A-GEN or any componentSevere hepatic impairmentConcurrent use with MAO inhibitors
| Precautions | Serotonin syndrome risk when co-administered with other serotonergic drugs; QT prolongation at high doses; hepatic impairment requires dose adjustment; discontinuation syndrome upon abrupt cessation. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase serum levels and risk of toxicity. No other significant food interactions known; take with or without food. |
| Clinical Pearls | SER-A-GEN is a combination of sertraline and a generic agent; monitor for serotonin syndrome when co-prescribed with other serotonergic drugs. Use with caution in patients with hepatic impairment; start at lower doses. Abrupt discontinuation may cause withdrawal symptoms; taper gradually. |
| Patient Advice | Take SER-A-GEN exactly as prescribed; do not stop without consulting your doctor. · It may take several weeks to feel the full benefit; continue taking it even if you feel well. · Avoid alcohol while taking this medication. · Report any symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness) immediately. · Do not take with other antidepressants or migraine medications without medical advice. |
Loading safety data…